Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. cut its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 11.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,972 shares of the company’s stock after selling 38,500 shares during the period. Arcutis Biotherapeutics comprises about 1.0% of Privium Fund Management B.V.’s holdings, making the stock its 19th largest position. Privium Fund Management B.V.’s holdings in Arcutis Biotherapeutics were worth $5,768,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. AQR Capital Management LLC boosted its position in shares of Arcutis Biotherapeutics by 21.4% during the 1st quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock worth $3,882,000 after acquiring an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Arcutis Biotherapeutics by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock valued at $1,118,000 after purchasing an additional 2,063 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Arcutis Biotherapeutics in the second quarter valued at approximately $217,000. Fishman Jay A Ltd. MI increased its stake in Arcutis Biotherapeutics by 4.3% in the second quarter. Fishman Jay A Ltd. MI now owns 556,150 shares of the company’s stock valued at $7,797,000 after purchasing an additional 23,000 shares during the last quarter. Finally, KLP Kapitalforvaltning AS raised its holdings in Arcutis Biotherapeutics by 17.8% during the second quarter. KLP Kapitalforvaltning AS now owns 21,800 shares of the company’s stock worth $306,000 after purchasing an additional 3,300 shares in the last quarter.

Arcutis Biotherapeutics Stock Down 1.4%

Arcutis Biotherapeutics stock opened at $25.37 on Friday. The stock has a 50 day moving average of $28.52 and a two-hundred day moving average of $22.16. Arcutis Biotherapeutics, Inc. has a twelve month low of $11.13 and a twelve month high of $31.77. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of -70.47 and a beta of 1.71. The company has a current ratio of 3.50, a quick ratio of 3.28 and a debt-to-equity ratio of 0.68.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Arcutis Biotherapeutics had a negative return on equity of 29.69% and a negative net margin of 13.94%.The business had revenue of $99.22 million during the quarter, compared to analysts’ expectations of $86.69 million. As a group, research analysts expect that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Neha Krishnamohan sold 40,504 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $23.20, for a total transaction of $939,692.80. Following the transaction, the director directly owned 22,123 shares in the company, valued at $513,253.60. The trade was a 64.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sue-Jean Lin sold 25,272 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $30.78, for a total value of $777,872.16. Following the completion of the sale, the director directly owned 26,735 shares in the company, valued at $822,903.30. This represents a 48.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 253,912 shares of company stock worth $6,884,105 in the last ninety days. Insiders own 9.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on ARQT shares. Needham & Company LLC upped their target price on shares of Arcutis Biotherapeutics from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 26th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Monday, December 29th. The Goldman Sachs Group lifted their target price on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Finally, Zacks Research cut Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.20.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.